CTNMContineum Therapeutics, Inc.
$13.21+16% 1Y
$13.21
$9.1752 weeks$17.56
Price
+16%1YEnd-of-day closes, not the intraday tick.
The five questions
2 of 5 availableOnly two of the five can be answered for CTNM today. The rest need figures this filer has not published. The tabs above still show whatever data does exist.
- Is the business good?not enough filed
- Is it safe?Watch
- Is the price fair?not enough filed
- Is it growing?not enough filed
- What is the market doing?Mixed
P/En/a
Market value$493.9M
1 year+16%
5 yearsn/a
Charts
As reported to the SEC, without any scoring.
The next results filing is expected around Oct 29, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 14, 2026On September 14, 2026, Contineum Therapeutics, Inc. (“Contineum”) issued a press release in which it reported the results of the MOONLIGHT-1 Phase 2 clinical trial evaluating the efficacy, safety, and tolerability of JNJ-5120/PIPE-307 as a monotherapy in adult participants with major depressive disorder.Other event · Form 8-K
- Jul 30, 2026Key Clinical Development Milestones.Earnings release · press release
- May 5, 2026Key Clinical Development Milestones.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Biotechnology
The closest names by size in the same industry